MENLO PARK, Calif.--(BUSINESS WIRE)--July 5, 2006--Geron Corporation (Nasdaq:GERN - News) today announced the presentation of new data that document the company’s progress in the development of first-in-class therapeutic products from human embryonic stem cells (hESCs) for the treatment of degenerative diseases.
